200 related articles for article (PubMed ID: 24947046)
1. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis.
Huang Y; Litvinov IV; Wang Y; Su MW; Tu P; Jiang X; Kupper TS; Dutz JP; Sasseville D; Zhou Y
Oncotarget; 2014 Jun; 5(12):4418-25. PubMed ID: 24947046
[TBL] [Abstract][Full Text] [Related]
2. TOX acts an oncological role in mycosis fungoides.
Yu X; Luo Y; Liu J; Liu Y; Sun Q
PLoS One; 2015; 10(3):e0117479. PubMed ID: 25811617
[TBL] [Abstract][Full Text] [Related]
3. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers of early-stage mycosis fungoides.
Zhang Y; Wang Y; Yu R; Huang Y; Su M; Xiao C; Martinka M; Dutz JP; Zhang X; Zheng Z; Zhou Y
J Invest Dermatol; 2012 Jun; 132(6):1698-706. PubMed ID: 22377759
[TBL] [Abstract][Full Text] [Related]
5. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
6. TOX Expression in Mycosis Fungoides and Sezary Syndrome.
Pileri A; Cavicchi M; Bertuzzi C; Righi S; Zengarini C; Sabattini E; Roncador G; Agostinelli C
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885488
[TBL] [Abstract][Full Text] [Related]
7. Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.
Ibrahim MA; Mohamed A; Soltan MY
Indian J Dermatol Venereol Leprol; 2021; 87(6):819-825. PubMed ID: 31857520
[TBL] [Abstract][Full Text] [Related]
8. miRNA expression profiling of mycosis fungoides.
van Kester MS; Ballabio E; Benner MF; Chen XH; Saunders NJ; van der Fits L; van Doorn R; Vermeer MH; Willemze R; Tensen CP; Lawrie CH
Mol Oncol; 2011 Jun; 5(3):273-80. PubMed ID: 21406335
[TBL] [Abstract][Full Text] [Related]
9. TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.
Ahmed MM; Hegazy AA; Embaby A; Nawwar EM; Hegazy SA; Ibrahim HM; Gobran MA
Turk Patoloji Derg; 2023; 39(1):15-22. PubMed ID: 35642346
[TBL] [Abstract][Full Text] [Related]
10. TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoides.
Örnek S; Ozekinci S; Ipin T; Kocaturk E
J Cutan Pathol; 2024 Mar; 51(3):232-238. PubMed ID: 37932931
[TBL] [Abstract][Full Text] [Related]
11. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
14. Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.
Garaicoa FH; Roisman A; Arias M; Trila C; Fridmanis M; Abeldaño A; Vanzulli S; Narbaitz M; Slavutsky I
Tumour Biol; 2016 Oct; 37(10):13637-13647. PubMed ID: 27473081
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
16. Altered microRNA expression in folliculotropic and transformed mycosis fungoides.
Marosvári D; Téglási V; Csala I; Marschalkó M; Bödör C; Timár B; Csomor J; Hársing J; Reiniger L
Pathol Oncol Res; 2015 Jul; 21(3):821-5. PubMed ID: 25698383
[TBL] [Abstract][Full Text] [Related]
17. Decreased progranulin expression in Mycosis fungoides: a possible association with the high frequency of skin infections.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
Eur J Dermatol; 2018 Dec; 28(6):790-794. PubMed ID: 30530405
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
19. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
[TBL] [Abstract][Full Text] [Related]
20. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
